Advancing Therapeutic Strategies for Triple-Negative Breast Cancer Through Proteasome Inhibition

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen, progesterone, and HER2 receptors, rendering it unresponsive to hormonal and targeted therapies. As a result, chemotherapy remains the primary treatment, often associated with high recurrence rates and poor outcomes due to resistance.

Dr. Khor Poh Yen, a scientist from Faculty of Pharmacy & Health Sciences, Universiti Kuala Lumpur (UniKL) is advancing research in this field through her work on a synthetic compound that has been shown to block the cell cycle, induce apoptosis, and downregulate proteasome activity in human TNBC cells. Her study postulates that this compound prevents the degradation of pro-apoptotic and cell cycle-regulating proteins by inhibiting proteasome activity, offering a promising new therapeutic approach for TNBC.

To further understand the compound’s mechanism, a proteome profiler array from R&D Systems was performed to identify the proteins targeted by the proteasome and analyze their expression after treatment with the compound.

"We collaborated with Biomed Global for the ubiquitin-proteome profiler assay and had a great experience working with their team of technical experts. They provided professional consultation and delivered high-quality services.".